Ignite Creation Date:
2024-05-06 @ 8:23 PM
Last Modification Date:
2024-10-26 @ 3:26 PM
Study NCT ID:
NCT06360250
Status:
NOT_YET_RECRUITING
Last Update Posted:
2024-04-11
First Post:
2024-04-07
Brief Title:
Safety Tolerability Pharmacokinetics Pharmacodynamics and Immunogenicity of the Fully Human Anti-tetanus Toxin Monoclonal Antibody A82 B86 Injection Combination Formulation
Sponsor:
Changchun BCHT Biotechnology Co
Organization:
Changchun BCHT Biotechnology Co
Organization Data
Organization:
Changchun BCHT Biotechnology Co
Class:
INDUSTRY
Study ID:
B2001-F20220601
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Changchun BCHT Biotechnology Co
Lead Sponsor Class:
INDUSTRY
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None
Collaborators
| Name | Class |
|---|---|
| Anning City First Peoples Hospital | UNKNOWN |
| The First Affiliated Hospital of Yunnan University of Traditional Chinese Medicine | UNKNOWN |